New hope for advanced breast cancer: experimental drug targets tumors after other treatments fail
NCT ID NCT04829604
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called ARX788 in people with HER2-positive breast cancer that has spread and no longer responds to standard treatments. About 72 adults will receive the drug to see if it shrinks tumors and how long that effect lasts. The goal is to find a new option for controlling the disease when other therapies stop working.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Los Angeles, California, 90033, United States
-
Research Site
Newport Beach, California, 92663, United States
-
Research Site
San Francisco, California, 94158, United States
-
Research Site
Whittier, California, 90602, United States
-
Research Site
Atlanta, Georgia, 30322, United States
-
Research Site
Chicago, Illinois, 60611, United States
-
Research Site
Louisville, Kentucky, 40207, United States
-
Research Site
Silver Spring, Maryland, 20904, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
Omaha, Nebraska, 68130, United States
-
Research Site
Las Vegas, Nevada, 89128, United States
-
Research Site
Camden, New Jersey, 08103, United States
-
Research Site
New Hyde Park, New York, 11042, United States
-
Research Site
New York, New York, 10028, United States
-
Research Site
Shirley, New York, 11967, United States
-
Research Site
The Bronx, New York, 10469, United States
-
Research Site
Portland, Oregon, 97213, United States
-
Research Site
Tigard, Oregon, 97223, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Dallas, Texas, 75246, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
San Antonio, Texas, 78229, United States
-
Research Site
Norfolk, Virginia, 23502, United States
-
Research Site
Tacoma, Washington, 98405, United States
-
Research Site
Frankston, Victoria, 3199, Australia
-
Research Site
Geelong, Victoria, 3220, Australia
-
Research Site
Nedlands, Western Australia, 6009, Australia
-
Research Site
Daegu, 42601, South Korea
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 02841, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could immune activators revive treatment for Hard-to-Treat breast cancer?
- DNA vaccine aims to train immune system against breast cancer
- New drug challenger takes on leading therapy for advanced breast cancer
- Spinal fluid may hold clues to breast cancer brain spread
- New cocktail of drugs aims to keep HER2+ breast cancer in check
- Kazakhstan cancer study to reveal Real-World treatment patterns